Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Conditions
Pain, Postoperative
Interventions
N1539, Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
35 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Florence, Alabama • Mobile, Alabama • Sheffield, Alabama + 3 more
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

Evaluation of Preoperative N1539 in Colorectal Surgery

NCT03323385
Conditions
Pain, Postoperative
Interventions
N1539, Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Florence, Alabama • Mobile, Alabama • Miami, Florida + 6 more
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Conditions
Shoulder Pain, Opioid Use
Interventions
Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Ovulation in Obese Women

NCT06306131
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Completed Phase 2 Interventional

HTX-011 in Spinal Surgery

NCT04911062
Conditions
Post-Operative Pain, Lumbar Laminectomy
Interventions
Bupivacaine HCI without epinephrine, HTX-011, Luer Lock Applicator
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
12
States / cities
Phoenix, Arizona • Pasadena, California • Wichita, Kansas + 9 more
Conditions
ACL Surgery, Pain Management
Interventions
Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
13 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Postoperative Pain
Interventions
HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
8
States / cities
Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more
Completed Phase 2 Interventional Results available

Pilot Herniorrhaphy Study for Postoperative Analgesia

NCT02504580
Conditions
Postoperative Pain
Interventions
HTX-011, Placebo, HTX-002, Bupivacaine HCI (Marcaine), HTX-011A, HTX-011B, HTX-009
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Anaheim, California • Houston, Texas
Conditions
Postoperative Pain, Acute, Skin Cancer
Interventions
Meloxicam 7.5 mg, Meloxicam 15 mg, Acetaminophen 500mg
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 110 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

NCT00618163
Conditions
Inflammation
Interventions
Meloxicam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pain, Post-operative
Interventions
N1539, Intravenous Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Pasadena, Maryland
Conditions
Migraine
Interventions
AXS-07
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Conditions
Rotator Cuff Repairs, Pain Management
Interventions
Multimodal Pain Regimen, Standard of Care Pain Regimen
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Bunionectomy HTX-011 Administration Study

NCT03718039
Conditions
Postoperative Pain
Interventions
HTX-011, Luer Lock applicator, Vial access device, aprepitant
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Osteoarthritis
Interventions
Meloxicam Test Capsules, Placebo Capsules
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
40
States / cities
Birmingham, Alabama • Carmichael, California • Pismo Beach, California + 31 more
Conditions
Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
Interventions
TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy
Device · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Postoperative Pain
Interventions
HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more
Conditions
Opioid Use, Pain, Post Operative
Interventions
nCAP Signal Relief Patch, Standard of Care
Device · Other
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2 Interventional Results available

HTX-011 for Post-bunionectomy Analgesia

NCT02471898
Conditions
Analgesia
Interventions
HTX-011, Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Pasadena, California
Conditions
Knee Pain Chronic
Interventions
Brief mindfulness, Mindfulness-Oriented Recovery Enhancement (MORE), Standard care
Behavioral · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Conditions
Dental Pain
Interventions
N1539, placebo, Motrin
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Contraception
Interventions
Ulipristal Acetate 30 MG Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California